Related Experiment Video
Updated: Jun 16, 2026
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
A Scoping Review on Cognition in Myelodysplastic Syndromes: Advances and Challenges
Anna Tsiakiri1, Konstantinos Frigkas2, Pinelopi Vlotinou3
1Department of Neurology, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Background/Objectives:
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis and a risk of progression to acute myeloid leukemia (AML). Cognitive impairments, including deficits in memory, attention, and executive function, are frequently reported in MDS patients. These impairments are linked to systemic inflammation, neurotoxic treatment effects, and the psychological burden of chronic disease. This review synthesizes existing evidence on cognitive dysfunction in MDS, highlighting knowledge gaps and opportunities for future research.
Methods:
A scoping review was conducted following PRISMA-ScR guidelines. MEDLINE and Scopus databases were searched for studies examining cognition in MDS patients, using terms like "myelodysplastic syndromes" and "cognition." Inclusion criteria were original, English-language studies reporting cognitive outcomes in MDS. Reviews, animal studies, and abstracts were excluded. Data on study design, patient characteristics, cognitive tests, and outcomes were extracted and descriptively analyzed.
Results:
The review included 25 studies involving 2390 patients with hematologic malignancies, 493 of whom had MDS. Key findings identified cognitive deficits primarily in attention, executive function, and memory. Systemic inflammation and treatment-related neurotoxicity were significant contributors, with older age compounding these effects. Longitudinal studies demonstrated persistent cognitive challenges post-treatment, though the severity varied by patient demographics and therapeutic regimens.
Conclusions:
Cognitive impairments in MDS are multifactorial and significantly impact patients' quality of life. Current research highlights the need for routine cognitive assessments and targeted interventions. Future studies should focus on longitudinal designs to explore specific cognitive domains and develop therapeutic strategies to mitigate cognitive decline.
Insights
Myelodysplastic syndromes (MDS) are linked to cognitive impairments like memory and attention deficits. Systemic inflammation and treatment side effects contribute, impacting patient quality of life.
Area of Science:
- Hematology
- Neuroscience
- Clinical Research
Background:
- Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders with ineffective hematopoiesis and risk of AML.
- Cognitive impairments (memory, attention, executive function) are common in MDS patients.
- These deficits are associated with inflammation, neurotoxicity, and disease burden.
Purpose of the Study:
- To synthesize evidence on cognitive dysfunction in myelodysplastic syndromes.
- To identify knowledge gaps and future research directions for cognitive impairments in MDS.
- To review the impact of MDS on cognitive function.
Main Methods:
- A scoping review following PRISMA-ScR guidelines was performed.
- Searched MEDLINE and Scopus for studies on cognition in MDS patients.
- Included original English-language studies reporting cognitive outcomes; excluded reviews and animal studies.
Main Results:
- 25 studies involving 2390 patients (493 with MDS) were analyzed.
- Cognitive deficits were prominent in attention, executive function, and memory.
- Systemic inflammation, neurotoxicity, and older age were key contributors; deficits persisted post-treatment.
Conclusions:
- Cognitive impairments in MDS are multifactorial and impact quality of life.
- Routine cognitive assessments and targeted interventions are needed for MDS patients.
- Future research should use longitudinal designs to develop mitigation strategies for cognitive decline.
